[<sup>68</sup>Ga]Ga-PSMA-11: The First FDA-Approved <sup>68</sup>Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
For the positron emission tomography (PET) imaging of prostate cancer, radiotracers targeting the prostate-specific membrane antigen (PSMA) are nowadays used in clinical practice. Almost 10 years after its discovery, [<sup>68</sup>Ga]Ga-PSMA-11 has been approved in the United States by t...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
MDPI AG,
2021-07-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | For the positron emission tomography (PET) imaging of prostate cancer, radiotracers targeting the prostate-specific membrane antigen (PSMA) are nowadays used in clinical practice. Almost 10 years after its discovery, [<sup>68</sup>Ga]Ga-PSMA-11 has been approved in the United States by the Food and Drug Administration (FDA) as the first <sup>68</sup>Ga-radiopharmaceutical for the PET imaging of PSMA-positive prostate cancer in 2020. This radiopharmaceutical combines the peptidomimetic Glu-NH-CO-NH-Lys(Ahx)-HBED-CC with the radionuclide <sup>68</sup>Ga, enabling specific imaging of tumor cells expressing PSMA. Such a targeting approach may also be used for therapy planning as well as potentially for the evaluation of treatment response. |
|---|---|
| Item Description: | 10.3390/ph14080713 1424-8247 |